New data from Prana's mid-stage study of lead product candidate...

New data from Prana's mid-stage study of lead product candidate in Huntington's disease showed improvements in thinking; shares up 11%

Jun 22 2016, 12:20 ET | About: Prana Biotechnology Ltd (PRAN) | By: Douglas W. House, SA News Editor

​

Thinly traded nano cap Prana Biotechnology (PRAN +11.3%) heads north on almost a 10x surge in volume, albeit on turnover of only 335K shares, in response to its announcement of new data from its completed Phase 2 clinical trial, REACH2HD, evaluating lead product candidate PBT2 in patients with Huntington's disease. The results were presented at the 20th Annual International Movement Disorder Society Congress in Berlin, Germany.
The new analysis showed that 90% of the study participants who self-reported an improvement in their thinking were on PBT2 treatment.
PBT2 is a metal protein attenuating compound (MPAC) which is designed to interrupt interactions between metals and target proteins in the brain and thereby prevent deterioration of brain cells.
No word is provided about the company's plans for Phase 3 studies.

http://seekingalpha.com/news/319008...d?source=email_rt_mc_readmore&dr=1#email_link